Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.

Bauman JE, Duvvuri U, Thomas S, Gooding WE, Clump DA, Karlovits B, Wehbe A, Miller FR, Kim S, Sen M, Heron DE, Grandis JR, Argiris A.

Cancer. 2018 Oct 1;124(19):3881-3889. doi: 10.1002/cncr.31651. Epub 2018 Oct 6.

PMID:
30291796
2.

Induced Bias Due to Crossover Within Randomized Controlled Trials in Surgical Oncology: A Meta-regression Analysis of Minimally Invasive versus Open Surgery for the Treatment of Gastrointestinal Cancer.

Garas G, Markar SR, Malietzis G, Ashrafian H, Hanna GB, Zacharakis E, Jiao LR, Argiris A, Darzi A, Athanasiou T.

Ann Surg Oncol. 2018 Jan;25(1):221-230. doi: 10.1245/s10434-017-6210-y. Epub 2017 Nov 6. Review.

3.

Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).

Argiris A, Lee JW, Stevenson J, Sulecki MG, Hugec V, Choong NW, Saltzman JN, Song W, Hansen RM, Evans TL, Ramalingam SS, Schiller JH.

Ann Oncol. 2017 Dec 1;28(12):3037-3043. doi: 10.1093/annonc/mdx534.

4.

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.

Argiris A, Harrington KJ, Tahara M, Schulten J, Chomette P, Ferreira Castro A, Licitra L.

Front Oncol. 2017 May 9;7:72. doi: 10.3389/fonc.2017.00072. eCollection 2017. Review.

5.

Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM.

Cancer. 2017 Aug 1;123(15):2936-2944. doi: 10.1002/cncr.30717. Epub 2017 May 4.

6.

Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.

Jie HB, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL.

Cancer Immunol Res. 2017 May;5(5):408-416. doi: 10.1158/2326-6066.CIR-16-0333. Epub 2017 Apr 13.

7.

Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.

Ferris RL, Geiger JL, Trivedi S, Schmitt NC, Heron DE, Johnson JT, Kim S, Duvvuri U, Clump DA, Bauman JE, Ohr JP, Gooding WE, Argiris A.

Ann Oncol. 2016 Dec;27(12):2257-2262. doi: 10.1093/annonc/mdw428. Epub 2016 Oct 11.

8.

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.

Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F.

J Thorac Oncol. 2017 Jan;12(1):145-151. doi: 10.1016/j.jtho.2016.09.131. Epub 2016 Sep 30.

9.

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J.

Cancer. 2016 Dec 1;122(23):3641-3649. doi: 10.1002/cncr.30317. Epub 2016 Sep 20.

10.

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.

Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, Martin D, Gutkind JS, Hedberg ML, Grandis JR, Argiris A.

Head Neck. 2016 Dec;38(12):1759-1764. doi: 10.1002/hed.24501. Epub 2016 May 27.

PMID:
27232378
11.

Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.

Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulou M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, Chiosea SI, Branstetter B, Ferris RL.

Ann Oncol. 2016 Aug;27(8):1594-600. doi: 10.1093/annonc/mdw204. Epub 2016 May 13.

12.

Characterization of human papillomavirus antibodies in individuals with head and neck cancer.

Lang Kuhs KA, Pawlita M, Gibson SP, Schmitt NC, Trivedi S, Argiris A, Kreimer AR, Ferris RL, Waterboer T.

Cancer Epidemiol. 2016 Jun;42:46-52. doi: 10.1016/j.canep.2016.03.003. Epub 2016 Mar 21.

13.

Emerging aspects of nanotoxicology in health and disease: From agriculture and food sector to cancer therapeutics.

Piperigkou Z, Karamanou K, Engin AB, Gialeli C, Docea AO, Vynios DH, Pavão MS, Golokhvast KS, Shtilman MI, Argiris A, Shishatskaya E, Tsatsakis AM.

Food Chem Toxicol. 2016 May;91:42-57. doi: 10.1016/j.fct.2016.03.003. Epub 2016 Mar 8. Review.

PMID:
26969113
14.

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE.

Ann Oncol. 2016 Feb;27(2):318-23. doi: 10.1093/annonc/mdv537. Epub 2015 Nov 23.

15.

p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study.

Ha CS, Michalek JE, Elledge R, Kelly KR, Ganapathy S, Su H, Jenkins CA, Argiris A, Swords R, Eng TY, Karnad A, Crownover RL, Swanson GP, Goros M, Pollock BH, Yuan ZM.

Mol Oncol. 2016 Jan;10(1):148-56. doi: 10.1016/j.molonc.2015.09.004. Epub 2015 Sep 18.

16.

EGFR inhibition for recurrent or metastatic HNSCC.

Argiris A.

Lancet Oncol. 2015 May;16(5):488-9. doi: 10.1016/S1470-2045(15)70178-6. Epub 2015 Apr 16. No abstract available.

PMID:
25892143
17.

CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.

Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, Whiteside TL, Ferris RL.

Cancer Res. 2015 Jun 1;75(11):2200-10. doi: 10.1158/0008-5472.CAN-14-2788. Epub 2015 Apr 1.

18.

Targeting angiogenesis in head and neck cancer.

Vassilakopoulou M, Psyrri A, Argiris A.

Oral Oncol. 2015 May;51(5):409-15. doi: 10.1016/j.oraloncology.2015.01.006. Epub 2015 Feb 10. Review.

PMID:
25680863
19.

Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.

Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA.

Clin Cancer Res. 2014 Oct 1;20(19):5041-51. doi: 10.1158/1078-0432.CCR-14-0051. Epub 2014 Aug 8.

20.

Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck.

Yao M, Galanopoulos N, Lavertu P, Fu P, Gibson M, Argiris A, Rezaee R, Zender C, Wasman J, Machtay M, Savvides P.

Head Neck. 2015 Nov;37(11):1665-71. doi: 10.1002/hed.23813. Epub 2014 Oct 29.

21.

Posttraumatic stress disorder symptoms in newly diagnosed patients with head and neck cancer and their partners.

Posluszny DM, Dougall AL, Johnson JT, Argiris A, Ferris RL, Baum A, Bovbjerg DH, Dew MA.

Head Neck. 2015 Sep;37(9):1282-9. doi: 10.1002/hed.23760. Epub 2014 Sep 17.

22.

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.

Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA, Burtness B, Mehra R.

Ann Oncol. 2014 Jul;25(7):1410-6. doi: 10.1093/annonc/mdu167. Epub 2014 May 5.

23.

Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.

Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, Wirth L, Nikiforova MN, Siegfried JM, Grandis JR.

Clin Cancer Res. 2014 Jun 15;20(12):3289-98. doi: 10.1158/1078-0432.CCR-13-3360. Epub 2014 Apr 11.

24.

Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL.

Clin Cancer Res. 2014 May 1;20(9):2433-44. doi: 10.1158/1078-0432.CCR-13-2617. Epub 2014 Feb 28.

25.

Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.

Tarhini AA, Zahoor H, McLaughlin B, Gooding WE, Schmitz JC, Siegfried JM, Socinski MA, Argiris A.

Anticancer Res. 2013 Oct;33(10):4475-81.

26.

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.

Ramalingam SS, Kotsakis A, Tarhini AA, Heron DE, Smith R, Friedland D, Petro DP, Raez LE, Brahmer JR, Greenberger JS, Dacic S, Hershberger P, Landreneau RJ, Luketich JD, Belani CP, Argiris A.

Lung Cancer. 2013 Sep;81(3):416-21. doi: 10.1016/j.lungcan.2013.06.002. Epub 2013 Jul 10.

PMID:
23849982
27.

Current status and future directions in induction chemotherapy for head and neck cancer.

Argiris A.

Crit Rev Oncol Hematol. 2013 Oct;88(1):57-74. doi: 10.1016/j.critrevonc.2013.03.001. Epub 2013 Mar 27. Review.

PMID:
23541071
28.

Pemetrexed in head and neck cancer: a systematic review.

Argiris A, Pennella E, Koustenis A, Hossain AM, Obasaju CK.

Oral Oncol. 2013 Jun;49(6):492-501. doi: 10.1016/j.oraloncology.2013.01.007. Epub 2013 Mar 7. Review.

PMID:
23466170
29.

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.

Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA.

J Clin Oncol. 2013 Apr 10;31(11):1405-14. doi: 10.1200/JCO.2012.45.4272. Epub 2013 Mar 4.

30.

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR Jr, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S.

Ann Oncol. 2013 Jan;24(1):220-5. doi: 10.1093/annonc/mds245. Epub 2012 Aug 16.

32.

Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.

Moskowitz HS, Gooding WE, Thomas SM, Freilino ML, Gross N, Argiris A, Grandis JR, Ferris RL.

Oral Oncol. 2012 Nov;48(11):1136-45. doi: 10.1016/j.oraloncology.2012.05.015. Epub 2012 Jun 23.

33.

Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.

Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL.

J Immunol Methods. 2012 Jul 31;381(1-2):14-22. doi: 10.1016/j.jim.2012.04.004. Epub 2012 Apr 13.

34.

Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.

Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM.

Clin Cancer Res. 2012 Apr 15;18(8):2278-89. doi: 10.1158/1078-0432.CCR-11-1593. Epub 2012 Feb 20.

35.

A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.

Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR.

J Thorac Oncol. 2012 Mar;7(3):574-8. doi: 10.1097/JTO.0b013e31823f43ca.

36.

Race and health disparities in patient refusal of surgery for early-stage non-small cell lung cancer: a SEER cohort study.

Mehta RS, Lenzner D, Argiris A.

Ann Surg Oncol. 2012 Mar;19(3):722-7. doi: 10.1245/s10434-011-2087-3. Epub 2011 Sep 27.

PMID:
21947698
37.

A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer.

Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, Murphy SC, Erlichman C, Rudin CM, Govindan R; Mayo Phase 2 Consortium; California Consortium.

J Thorac Oncol. 2011 Oct;6(10):1757-60. doi: 10.1097/JTO.0b013e31822e2941.

38.

Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer.

Argiris A, Lee SC, Feinstein T, Thomas S, Branstetter BF 4th, Seethala R, Wang L, Gooding W, Grandis JR, Ferris RL.

Oral Oncol. 2011 Oct;47(10):961-6. doi: 10.1016/j.oraloncology.2011.07.034. Epub 2011 Sep 1.

39.

Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.

Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ, Stoller RG, Grandis JR, Egloff AM.

Invest New Drugs. 2012 Aug;30(4):1575-84. doi: 10.1007/s10637-011-9732-3. Epub 2011 Sep 1.

40.

Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.

Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, Chen Z, Suksta N, Cooley-Zgela T, Ramanand SG, Ahsan A, Nyati MK, Wright JJ, Van Waes C.

Clin Cancer Res. 2011 Sep 1;17(17):5755-64. doi: 10.1158/1078-0432.CCR-11-0861. Epub 2011 Jul 12.

41.

XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.

Vaezi A, Wang X, Buch S, Gooding W, Wang L, Seethala RR, Weaver DT, D'Andrea AD, Argiris A, Romkes M, Niedernhofer LJ, Grandis JR.

Clin Cancer Res. 2011 Aug 15;17(16):5513-22. doi: 10.1158/1078-0432.CCR-11-0086. Epub 2011 Jul 7.

42.

Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab.

Bhola NE, Thomas SM, Freilino M, Joyce S, Sahu A, Maxwell J, Argiris A, Seethala R, Grandis JR.

Clin Cancer Res. 2011 Aug 1;17(15):4996-5004. doi: 10.1158/1078-0432.CCR-10-3406. Epub 2011 Jun 8.

43.

Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.

Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE.

Ann Oncol. 2011 Nov;22(11):2482-8. doi: 10.1093/annonc/mdr002. Epub 2011 Mar 1.

44.

Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.

Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, Savvides P, Romkes M.

J Clin Oncol. 2011 Mar 20;29(9):1140-5. doi: 10.1200/JCO.2010.33.3591. Epub 2011 Feb 22.

45.

Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy.

Feinstein TM, Lai SY, Lenzner D, Gooding W, Ferris RL, Grandis JR, Myers EN, Johnson JT, Heron DE, Argiris A.

Head Neck. 2011 Mar;33(3):318-23. doi: 10.1002/hed.21444. Epub 2011 Jan 31.

46.

Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.

Lara PN Jr, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR.

Clin Lung Cancer. 2011 Jan;12(1):33-7. doi: 10.3816/CLC.2011.n.004.

47.
48.

Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer.

Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, Branstetter BF, Posluszny DM, Wang L, Seethala RR, Dacic S, Gooding W, Grandis JR, Johnson JT, Ferris RL.

J Clin Oncol. 2010 Dec 20;28(36):5294-300. doi: 10.1200/JCO.2010.30.6423. Epub 2010 Nov 15.

49.

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, Belani CP, Dacic S, Argiris A.

Clin Cancer Res. 2010 Dec 1;16(23):5900-7. doi: 10.1158/1078-0432.CCR-10-0802. Epub 2010 Nov 2.

50.

A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer.

Tarhini AA, Belani CP, Luketich JD, Argiris A, Ramalingam SS, Gooding W, Pennathur A, Petro D, Kane K, Liggitt D, Championsmith T, Zhang X, Epperly MW, Greenberger JS.

Hum Gene Ther. 2011 Mar;22(3):336-42. doi: 10.1089/hum.2010.078. Epub 2011 Feb 2.

Supplemental Content

Loading ...
Support Center